A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Status:
Withdrawn
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of
rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the
toxicities of ABI-010 alone and in combination with ABI-007.